Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al.
Vladutiu
Georgirene
G
D003067:Coenzymes; D004198:Disease Susceptibility; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008305:Malignant Hyperthermia / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D012206:Rhabdomyolysis / Q000139:chemically induced; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics / Q000378:metabolism; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000235:genetics / Q000378:metabolism
D003067:Coenzymes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019837:Ryanodine Receptor Calcium Release Channel; D014451:Ubiquinone; C024989:coenzyme Q10